AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
23 nov. 2020 08h30 HE
|
ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
02 nov. 2020 08h30 HE
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
07 oct. 2020 08h30 HE
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality
05 oct. 2020 16h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19
21 sept. 2020 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h15 HE
|
ARCA biopharma, Inc.
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators
07 juil. 2020 08h30 HE
|
ARCA biopharma, Inc.
Integrin A5 may be a new target for intervening in the cell infectious processFindings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving...
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering
03 juin 2020 09h55 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
ARCA Biopharma Announces $9.4 Million Registered Direct Offering
01 juin 2020 08h20 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
28 mai 2020 08h00 HE
|
ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...